Funder: Breakthrough T1D

Due Dates: October 29, 2025 (Letter of Intent) | January 13, 2026 (Full proposal)

Funding Amounts: Up to $3,000,000 total over 3 years; budget commensurate with project scope (10% indirects for nonprofits; no indirects for for-profits)

Summary: Supports clinical trials to advance therapies for cardiovascular disease in people with type 1 diabetes, aiming to improve cardiovascular outcomes in this population.

Key Information: LOI approval required before full proposal; for-profit applications require company matching funds and prior discussion with program staff.